Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

By Miller Rg, Mitchell Jd, Lyon M, Moore Dh. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders, 2003

1,031 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Autophagy and apoptosis dysfunction in neurodegenerative disorders. (2014, neutral): “Currently, riluzole is the only therapy available on the market, however, the median prolonged life expectancy is only 2–3 months (Miller et al., 2012).”
Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence? (2015, background): “Finally, the only approved drug to treat ALS, which increases survival by 2–3 months (Miller et al., 2012), acts as an inhibitor of NMDA and kainate receptors (Debono et al., 1993) as well as rapidly upregulating EAAT activity in synaptosomes (Azbill et al., 2000).”
A comprehensive review of amyotrophic lateral sclerosis (2015, background): “[201] Other than riluzole, no other new treatment has been identified that be able to increase the ALS life expectancy.[199] Palliative care can help with the management of ALS symptoms and improving the quality of life.”